Lupin Ltd (LUPIN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Lupin Ltd (LUPIN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH61242D
  • |
  • Pages: 76
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Lupin Ltd (Lupin) is transnational pharmaceutical company. It is one of the leading generic pharmaceutical companies across the world. The company focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, anti-infectives, NSAIDs, anti-TB and cephalosporins. The company undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. It has operations in various countries worldwide including India, the US, the UK, Germany, Japan, South Africa, Philippines, and Australia. Lupin is headquartered in Mumbai, Maharashtra, India.

Lupin Ltd (LUPIN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

Lupin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10

Lupin Ltd, Medical Devices Deals, 2011 to YTD 2017 12

Lupin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13

Lupin Ltd, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Novartis May Sell Respiratory Drugs Portfolio 16

Bayer May Sell Dermatology Business 17

Kyowa Pharma to Acquire 21 Products from Shionogi 18

Lupin to Acquire Product Portfolio from Temmler Pharma 19

Lupin Plans To Acquire US Branded Drugs 20

Lupin Acquires Worldwide Rights To Goanna Brand From Aspen Pharmacare 21

Partnerships 22

Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 22

Boehringer Ingelheim Enters into Co-Marketing Agreement with Lupin 22

Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 23

Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 24

Lupin Enters into Development Agreement with Celon for Generic Advair Diskus 25

Lupin Enters into Co-Development Agreement with Merck Serono 25

Lupin Enters into Distribution Agreement with Salix Pharma 26

Lupin Enters into Distribution Agreement with LG Life Sciences for Insulin Analogue Glargine 27

Lupin Enters Into Joint Venture Agreement With Yoshindo To Form YL Biologics 28

Gavis Pharma Partners with Modavar Pharma 29

Lupin Enters Into Co-Promotion Agreement With Onset Dermatologics For Locoid Lotion 29

Lupin Plans Co-Marketing Agreement For Vaccines 30

Lupin Plans Marketing Agreement For Cardiovascular, Diabetes, Gynecology And Respiratory Drugs 30

Multicare Pharma Enters Into Co-Marketing Agreement With Sanofi 31

Eli Lilly and Company (India) Expands its Agreement With Lupin 32

Lupin Enters Into Joint Development Agreement With Medicis 33

Lupin Enters Into Co-Marketing Agreement With Natco Pharma 34

Licensing Agreements 35

Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 35

Lupin Enters into Licensing Agreement with Medicines Patent Pool 35

Romark Labs Enters Into Licensing Agreement With Lupin For Alinia 36

Merck Enters Into Licensing Agreement With Lupin 37

Lupin Enters Into Licensing Agreement With NeuClone 38

Lupin Enters Into Patent Licensing Agreement With Abbott For Antara 39

Salix Pharma Extends Licensing Agreement With Lupin 39

Equity Offering 40

Lupin Plans to Raise USD1.2 Billion in Public Offering of Equity Securities 40

Asset Transactions 41

G&W Labs to Acquire Two Generic Drugs of Gavis Pharma from Lupin 41

Lupin to Acquire Product Portfolio from Temmler Pharma 42

Acquisition 43

Lupin Acquires GAVIS Pharma for USD880 Million 43

Lupin May Acquire Sinclair IS Pharma for USD500 Million 44

Lupin Acquires Biocom 45

Lupin Acquires Medquimica 45

Lupin to Acquire Remaining 40% Stake in Pharma Dynamics 46

Lupin Acquires Labs Grin, Ophthalmology Therapies Provider 47

Lupin Plans to Acquire Generics Manufacturing Companies In Europe for up to USD1 Billion 48

Lupin Acquires Nanomi 49

Gavis Pharma Revises Open Offer Price To Acquire Additional 26% Stake In Wintac For US$5 Million 49

Aenova Completes Acquisition Of Temmler Pharma, Contract Manufacturing Company 50

Lupin Completes Acquisition Of I'rom Pharma 51

Lupin Ltd-Key Competitors 53

Key Employees 54

Locations And Subsidiaries 56

Head Office 56

Other Locations & Subsidiaries 56

Recent Developments 60

Financial Announcements 60

Feb 09, 2017: Lupin Quarter III Results, FY2017 60

Nov 09, 2016: Lupin's Quarter II, FY2017-Results 63

Aug 09, 2016: Lupin: Record Sales Profits-Quarter I FY2017 65

Aug 09, 2016: Lupin announces first quarter ended June 30, 2016 financila results 67

May 19, 2016: Record Sales & Profits-A New High Quarter IV & Annual Results-FY2016 Q4 FY2016 Net Sales up 34.0%, EBITDA up 72.7%, Net profit up 47.5% Proposed Dividend 375% 68

Feb 05, 2016: Lupin Announces the results for the quarter ended December 31, 2015 70

Corporate Communications 71

Apr 05, 2016: Lupin Appoints Dr. Kurt Nielsen as President of Lupin-Somerset 71

Legal and Regulatory 72

Nov 04, 2016: Lupin Receives EIR From US FDA for Goa, March 2016 Inspection 72

Jul 07, 2016: Lupin receives EIR from US FDA for Goa, July 2015 Inspection 73

May 26, 2016: Lupin announces closure of US FDA Audits for its Mandideep and Aurangabad Facilities 74

Product News 75

03/16/2017: Lupin launches Generic Minastrin 24 Fe chewable tablets in the US 75

Appendix 76

Methodology 76

About GlobalData 76

Contact Us 76

Disclaimer 76

List of Figures

Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10

Lupin Ltd, Medical Devices Deals, 2011 to YTD 2017 12

List of Tables

Lupin Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

Lupin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

Lupin Ltd, Deals By Therapy Area, 2011 to YTD 2017 10

Lupin Ltd, Medical Devices Deals, 2011 to YTD 2017 12

Lupin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13

Novartis May Sell Respiratory Drugs Portfolio 16

Bayer May Sell Dermatology Business 17

Kyowa Pharma to Acquire 21 Products from Shionogi 18

Lupin to Acquire Product Portfolio from Temmler Pharma 19

Lupin Plans To Acquire US Branded Drugs 20

Lupin Acquires Worldwide Rights To Goanna Brand From Aspen Pharmacare 21

Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 22

Boehringer Ingelheim Enters into Co-Marketing Agreement with Lupin 22

Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 23

Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 24

Lupin Enters into Development Agreement with Celon for Generic Advair Diskus 25

Lupin Enters into Co-Development Agreement with Merck Serono 25

Lupin Enters into Distribution Agreement with Salix Pharma 26

Lupin Enters into Distribution Agreement with LG Life Sciences for Insulin Analogue Glargine 27

Lupin Enters Into Joint Venture Agreement With Yoshindo To Form YL Biologics 28

Gavis Pharma Partners with Modavar Pharma 29

Lupin Enters Into Co-Promotion Agreement With Onset Dermatologics For Locoid Lotion 29

Lupin Plans Co-Marketing Agreement For Vaccines 30

Lupin Plans Marketing Agreement For Cardiovascular, Diabetes, Gynecology And Respiratory Drugs 30

Multicare Pharma Enters Into Co-Marketing Agreement With Sanofi 31

Eli Lilly and Company (India) Expands its Agreement With Lupin 32

Lupin Enters Into Joint Development Agreement With Medicis 33

Lupin Enters Into Co-Marketing Agreement With Natco Pharma 34

Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 35

Lupin Enters into Licensing Agreement with Medicines Patent Pool 35

Romark Labs Enters Into Licensing Agreement With Lupin For Alinia 36

Merck Enters Into Licensing Agreement With Lupin 37

Lupin Enters Into Licensing Agreement With NeuClone 38

Lupin Enters Into Patent Licensing Agreement With Abbott For Antara 39

Salix Pharma Extends Licensing Agreement With Lupin 39

Lupin Plans to Raise USD1.2 Billion in Public Offering of Equity Securities 40

G&W Labs to Acquire Two Generic Drugs of Gavis Pharma from Lupin 41

Lupin to Acquire Product Portfolio from Temmler Pharma 42

Lupin Acquires GAVIS Pharma for USD880 Million 43

Lupin May Acquire Sinclair IS Pharma for USD500 Million 44

Lupin Acquires Biocom 45

Lupin Acquires Medquimica 45

Lupin to Acquire Remaining 40% Stake in Pharma Dynamics 46

Lupin Acquires Labs Grin, Ophthalmology Therapies Provider 47

Lupin Plans to Acquire Generics Manufacturing Companies In Europe for up to USD1 Billion 48

Lupin Acquires Nanomi 49

Gavis Pharma Revises Open Offer Price To Acquire Additional 26% Stake In Wintac For US$5 Million 49

Aenova Completes Acquisition Of Temmler Pharma, Contract Manufacturing Company 50

Lupin Completes Acquisition Of I'rom Pharma 51

Lupin Ltd, Key Competitors 53

Lupin Ltd, Key Employees 54

Lupin Ltd, Other Locations 56

Lupin Ltd, Subsidiaries 56

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Lupin Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16190
Site License
USD 500 INR 32380
Corporate User License
USD 750 INR 48570

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com